Average Co-Inventor Count = 9.73
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (20 from 3,684 patents)
2. Universitéde Montreal (6 from 183 patents)
3. Ensemble Therapeutics Corporation (1 from 5 patents)
21 patents:
1. 12084452 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
2. 11492375 - Cyclic peptide immunomodulators
3. 10822343 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
4. 10538555 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
5. 10450347 - Immunomodulators
6. 10428077 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
7. 10358463 - Immunomodulators
8. 10143746 - Immunomodulators
9. 10047103 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
10. 9944678 - Immunomodulators
11. 9879046 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
12. 9862730 - Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
13. 9850283 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
14. 9688695 - Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
15. 9605022 - Macrocyclic compounds for inhibition of inhibitors of apoptosis